What did Roche Holding pay for GenMark Diagnostics?

Roche Holding acquired GenMark Diagnostics for $1.80B in 2021 (120.8x EBITDA), equivalent to 8.60x revenue. Target revenue was approximately $209.6M. Target EBITDA was approximately $14.9M.

What does GenMark Diagnostics do?

GenMark Diagnostics is a laboratory services business.

What multiple did Roche Holding pay for GenMark Diagnostics?

120.8x EBITDA and 8.60x revenue, based on disclosed deal value of $1.80B and disclosed financials.

M&A TRANSACTION · 2021

GenMark Diagnostics acquired by Roche Holding

$1.80B· 120.8x EBITDA· 8.60x revenue

Target

GenMark Diagnostics

Acquirer

Roche Holding

Strategic buyer

Disclosed financials at time of acquisition

Revenue

$209.6M

EBITDA

$14.9M

Deal Value

$1.80B

EV/EBITDA

120.8x

Context

This $1.80B acquisition of GenMark Diagnostics by Roche Holding sits in the laboratory services sub-vertical. The 120.8x EBITDA multiple paid in 2021 can be compared against the population median for laboratory services transactions of similar size on our Laboratory Services valuation hub. Roche Holding is acquiring as a strategic buyer; see how strategic acquirers typically price laboratory services businesses on our Laboratory Services strategic buyer-pool page.

Source

Data sourced from SEC Fairness Opinion — primary source. All figures reflect disclosed values at the time of the acquisition; no estimated or imputed data. Methodology

Value your own laboratory services

Get an instant valuation range for your business. Backed by 25,592 real M&A transactions.

Compare your business to the GenMark Diagnostics acquisition.

Citation: ExitValue.ai. (2021). GenMark Diagnostics acquired by Roche Holding. https://exitvalue.ai/deals/genmark-diagnostics-acquired-by-roche-holding-fairness-opi